A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib

Authors:

Abstract
No abstract available
Funding Information
  • National Cancer Institute (UM1 CA186709)

This publication has 33 references indexed in Scilit: